<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04038944</url>
  </required_header>
  <id_info>
    <org_study_id>18-19</org_study_id>
    <nct_id>NCT04038944</nct_id>
  </id_info>
  <brief_title>Anticoagulant and Antiarrhythmic Management Based on Continuous Rhythm Monitoring</brief_title>
  <official_title>Anticoagulant and Antiarrhythmic Management Based on Continuous Rhythm Monitoring and Cardiac Imaging in Patients at Low Risk for Cardiovascular Events Following Direct Current Cardioversion for New Onset Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Francis Hospital, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Francis Hospital, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to assess the feasibility and safety of using an ILR to identify the
      incidence of recurrent AF after an episode of newly diagnosed AF. The study further aims to
      assess the risk of AF recurrence in this low risk population based on left atrial and left
      atrial appendage anatomic and functional indices in addition to the standardized clinical
      CHA2DS2-Vasc score.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a significant incidence of recurrent AF following initial diagnosis of AF.

      Inclusion of left atrial (LA) and left atrial appendage (LAA) abnormalities together with
      risk prediction of CVA using CHA2DS2-Vasc score will identify patients at low or high risk
      for adverse cardiovascular events in patients with manifest and silent AF.

      Patients requiring cardioversion have higher risk of recurrent AF in follow up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to AF recurrence</measure>
    <time_frame>3 years</time_frame>
    <description>Time to AF recurrence based on clinical or ILR monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>30 days; 6 months; 1 year; 2 years; 3 years</time_frame>
    <description>Composite endpoint of all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF related re hospitalizations</measure>
    <time_frame>3 years</time_frame>
    <description>any hospitalization related to AFib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of CVA</measure>
    <time_frame>3 years</time_frame>
    <description>Stroke mRs&gt;1 or TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and minor bleeding</measure>
    <time_frame>3 years</time_frame>
    <description>events of major and minor bleeding</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>New Onset Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Subjects with new onset atrial fibrillation</arm_group_label>
    <description>Subjects with new onset atrial fibrillation who may or may not require electrical cardioversion</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The trial will include 250 subjects who have been identified with initial diagnosis of AF
        and for whom a rhythm control strategy has been chosen with the primary endpoint being time
        to AF recurrence, AF burden, and AF management at 1 and 3 years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Newly diagnosed AF

          3. Patient or legal guardian is willing and able to provide informed written consent and
             comply with follow-up visits and testing schedule

        Exclusion Criteria:

          1. Patient is participating in or plans to participate in any other investigational drug
             or device clinical trial that has not reached its primary endpoint

          2. Patient received an organ transplant, or is on a waiting list.

          3. Patient is not able to follow instructions for remote monitoring 4 Prior history of AF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Francis Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph Levine, MD</last_name>
    <phone>516-742-5700</phone>
    <email>joseph.levine@chsli.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth S Haag, RN MPA</last_name>
    <phone>516 562-6790</phone>
    <email>elizabeth.haag@chsli.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Haag, BSN MPA</last_name>
      <phone>516-562-6790</phone>
      <email>elizabeth.haag@chsli.org</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Levine, MD</last_name>
      <phone>516-562-6646</phone>
      <email>joseph.levine@chsli.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Levine, MD</last_name>
      <phone>516-562-6646</phone>
    </contact>
    <contact_backup>
      <last_name>Elizabeth S Haag, RN MPA</last_name>
      <phone>516-562-6790</phone>
      <email>elizabeth.haag@chsli.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bai Y, Wang YL, Shantsila A, Lip GYH. The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Clinical Epidemiology of Atrial Fibrillation in Asia. Chest. 2017 Oct;152(4):810-820. doi: 10.1016/j.chest.2017.03.048. Epub 2017 Apr 17. Review.</citation>
    <PMID>28427968</PMID>
  </reference>
  <reference>
    <citation>Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res. 2017 Apr 28;120(9):1501-1517. doi: 10.1161/CIRCRESAHA.117.309732. Review.</citation>
    <PMID>28450367</PMID>
  </reference>
  <reference>
    <citation>Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22(8):983-8.</citation>
    <PMID>1866765</PMID>
  </reference>
  <reference>
    <citation>Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21;37(20):1582-90. doi: 10.1093/eurheartj/ehw054. Epub 2016 Feb 25.</citation>
    <PMID>26920728</PMID>
  </reference>
  <reference>
    <citation>Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.</citation>
    <PMID>29069359</PMID>
  </reference>
  <reference>
    <citation>Calenda BW, Fuster V, Halperin JL, Granger CB. Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. Nat Rev Cardiol. 2016 Sep;13(9):549-59. doi: 10.1038/nrcardio.2016.106. Epub 2016 Jul 7. Review.</citation>
    <PMID>27383079</PMID>
  </reference>
  <reference>
    <citation>Goldberger JJ, Arora R, Green D, Greenland P, Lee DC, Lloyd-Jones DM, Markl M, Ng J, Shah SJ. Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate. Circulation. 2015 Jul 28;132(4):278-91. doi: 10.1161/CIRCULATIONAHA.115.016795. Review.</citation>
    <PMID>26216085</PMID>
  </reference>
  <reference>
    <citation>Andersson T, Magnuson A, Bryngelsson IL, Frøbert O, Henriksson KM, Edvardsson N, Poçi D. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013 Apr;34(14):1061-7. doi: 10.1093/eurheartj/ehs469. Epub 2013 Jan 14.</citation>
    <PMID>23321349</PMID>
  </reference>
  <reference>
    <citation>Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67.</citation>
    <PMID>17577005</PMID>
  </reference>
  <reference>
    <citation>Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.</citation>
    <PMID>11343485</PMID>
  </reference>
  <reference>
    <citation>European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. Erratum in: Eur Heart J. 2011 May;32(9):1172.</citation>
    <PMID>20802247</PMID>
  </reference>
  <reference>
    <citation>Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.</citation>
    <PMID>11401607</PMID>
  </reference>
  <reference>
    <citation>Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindbäck J, Granger CB, Alexander JH, Gersh BJ, Hanna M, Harjola VP, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc. 2017 Jun 23;6(6). pii: e004851. doi: 10.1161/JAHA.116.004851.</citation>
    <PMID>28645934</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

